John Maraganore
CIK: 0001180432
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Oct 22, 2026RAPP
Rapport Therapeutics, Inc.
Purchase(P)Indirect8.2K shares at avg. $26.38$217K - Oct 22, 2026RAPP
Rapport Therapeutics, Inc.
Purchase(P)Indirect1.2K shares at avg. $26.92$32K - Oct 19, 2026CTY
CITY THERAPEUTICS, INC.
Conversion(C)Direct610.8K shares- - Oct 15, 2026CTY
CITY THERAPEUTICS, INC.
Award(A)DirectStock Option (Right to Buy)
22.6K shares- - Jul 10, 2026TAK
TAKEDA PHARMACEUTICAL CO LTD
Disposition(D)DirectTax Obligation Award
1.2K shares at avg. $4931.20- - Jul 1, 2026TAK
TAKEDA PHARMACEUTICAL CO LTD
Award(A)Direct3.8K shares- - Jun 24, 2026KYMR
Kymera Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
6.1K shares- - Jun 10, 2026RAPP
Rapport Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
15.2K shares- - Jun 3, 2026BEAM
Beam Therapeutics Inc.
Award(A)DirectStock Option (Right to Buy)
19.7K shares- - May 4, 2026COAG
Hemab Therapeutics Holdings, Inc.
Conversion(C)Direct18K shares- - May 4, 2026COAG
Hemab Therapeutics Holdings, Inc.
Conversion(C)Direct18K shares- - Jan 29, 2026COAG
Hemab Therapeutics Holdings, Inc.
Award(A)DirectWarrants (Right to Buy)
107.3K shares- - Jun 25, 2025KYMR
Kymera Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
16K shares- - Jun 17, 2025RAPP
Rapport Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
21.9K shares- - Jun 4, 2025BEAM
Beam Therapeutics Inc.
Award(A)DirectStock Option (Right to Buy)
33.7K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 22, 2026 |  RAPP Rapport Therapeutics, Inc. | Purchase(P) | 8,239 | $26.38 | $217,344 | Indirect |
| Oct 22, 2026 | RAPP Rapport Therapeutics, Inc. | Purchase(P) | 1,172 | $26.92 | $31,547 | Indirect |
| Oct 19, 2026 |  CTY CITY THERAPEUTICS, INC. | Conversion(C) | 610,759 | - | $0 | Direct |
| Oct 15, 2026 | CTY CITY THERAPEUTICS, INC. | Award(A) Stock Option (Right to Buy) | 22,649 | - | - | Direct |
| Jul 10, 2026 |  TAK TAKEDA PHARMACEUTICAL CO LTD | Disposition(D) Tax Obligation Award | 1,152 | $4931.20 | - | Direct |
| Jul 1, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | Award(A) | 3,800 | - | $0 | Direct |
| Jun 24, 2026 |  KYMR Kymera Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 6,068 | - | - | Direct |
| Jun 10, 2026 | RAPP Rapport Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 15,200 | - | - | Direct |
| Jun 3, 2026 |  BEAM Beam Therapeutics Inc. | Award(A) Stock Option (Right to Buy) | 19,676 | - | - | Direct |
| May 4, 2026 |  COAG Hemab Therapeutics Holdings, Inc. | Conversion(C) | 17,974 | - | $0 | Direct |
| May 4, 2026 | COAG Hemab Therapeutics Holdings, Inc. | Conversion(C) | 17,974 | - | $0 | Direct |
| Jan 29, 2026 | COAG Hemab Therapeutics Holdings, Inc. | Award(A) Warrants (Right to Buy) | 107,338 | - | - | Direct |
| Jun 25, 2025 | KYMR Kymera Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 16,000 | - | - | Direct |
| Jun 17, 2025 | RAPP Rapport Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 21,850 | - | - | Direct |
| Jun 4, 2025 | BEAM Beam Therapeutics Inc. | Award(A) Stock Option (Right to Buy) | 33,662 | - | - | Direct |
1-15 of 15 transactions
About MARAGANORE JOHN
MARAGANORE JOHN (SEC CIK 0001180432) files insider reports with the SEC as Director of Rapport Therapeutics, Inc. (RAPP), Director of CITY THERAPEUTICS, INC. (CTY) and Director of TAKEDA PHARMACEUTICAL CO LTD (TAK). Signal8 also holds filings tied to 3 other companies.
Signal8 holds 12 ownership filings by MARAGANORE JOHN (2 Form 3, 10 Form 4), filed between Jun 6, 2025 and Oct 22, 2026. Those filings report 15 transactions, from Jun 4, 2025 to Oct 22, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on MARAGANORE JOHN's filings is in CAMBRIDGE, MA.
Recent filings by MARAGANORE JOHN
- Oct 22, 2026: Open-market purchases of RAPP shares (2 lines, Form 4, code P).
- Oct 19, 2026: Conversion of CTY shares (Form 4, code C).
- Oct 15, 2026: Grant or award of CTY derivative securities (Form 4, code A).
- Jul 10, 2026: Disposition to issuer transaction of TAK derivative securities (Form 4, code D).
- Jul 1, 2026: Grant or award of TAK shares (Form 4, code A).
Other insiders filing for Rapport Therapeutics, Inc. (RAPP)
- HEALY JAMES, Director
- Ceesay Abraham, Chief Executive Officer
- Sanchez Ramiro, Director
- Silva Paul M, Director
- Young Wendy B., Director
- PAUL STEVEN M, Director